| Quarter | Holdings | Value ($000) | Top Holdings | Form Type | Date Filed | Filing ID |
|---|---|---|---|---|---|---|
| Q2 2026 | 13 | 602,220 | CRSP, WVE, VIR, BNTX | 13F-HR | 8/13/2026 | 000199937126017873 |
| Q1 2026 | 13 | 599,153 | CRSP, WVE, BNTX, VIR | 13F-HR | 5/14/2026 | 000199937126010742 |
| Q4 2025 | 15 | 799,022 | WVE, CRSP, BNTX, VIR | 13F-HR | 2/12/2026 | 000199937126003198 |
Investors who own more than 5% of a class must file a Schedule 13D or 13G. Each security where the latest filing since 12/18/2024 is a 13D, newest first.
| Issuer | % of Class | Filed | ||||
|---|---|---|---|---|---|---|
|
Spero Therapeutics, Inc.
13D/A
SPRO · 84833T103
|
16.4% |
3/28/2025
Event 3/27/2025
|
||||
| Under 5%, checked the "5 percent or less" box, or amended by a later filing (1) | ||||||
|
CureVac N.V.
13D/A
CVAC · N2451R105
|
0% |
12/5/2025
Event 12/3/2025
|
||||